High prevalence of malignant melanoma in Israeli patients with Parkinson's disease

Journal of Neural Transmission

Volumn 118, Issue 8, 2011, Pages 1199-1207

  Inzelberg, R ^a,o   Rabey, J M ^b,o   Melamed, E ^c,o   Djaldetti, R ^c,o   Reches, A ^d   Badarny, S ^e,p   Hassin Baer, S ^a,o   Cohen, O ^a,o   Trau, H ^a,o   Aharon Peretz, J ^f,p   Milo, R ^g,h   Schwartz, M ^i,p   Huberman, M ^j,o   Gilead, L ^d   Barchana, M ^k,l   Liphshiz, I ^l   Fitzer Attas, C ^m   Giladi, N ^n,o  

^a SHEBA MEDICAL CENTER   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e CARMEL MEDICAL CENTER   (Israel)

^f RAMBAM MEDICAL CENTER   (Israel)

^g BARZILAI MEDICAL CENTER   (Israel)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁱ BNAI ZION MEDICAL CENTER   (Israel)

^j MEIR MEDICAL CENTER   (Israel)

^k MINISTRY OF HEALTH   (Israel)

^l UNIVERSITY OF HAIFA   (Israel)

^m TEVA PHARMACEUTICALS   (Israel)

ⁿ TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^o TEL AVIV UNIVERSITY   (Israel)

^p TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

more..

Author keywords

Cancer; Epidemiology; Melanoma; Parkinson's disease Parkinsonism; Prevalence

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; ISRAEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; FEMALE; HUMANS; ISRAEL; MALE; MELANOMA; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; SKIN NEOPLASMS;

EID: 80051596535     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0580-2     Document Type: Article

References (34)

1. DH Abramson MR Rubenfeld 1984 Choroidal melanoma and levodopa JAMA 252 1011 1012 6748203 10.1001/jama.252.8.1011 1:STN:280:DyaL2c3mvVSrsQ%3D%3D
2. JM Bertoni JP Arlette HH Fernandez C Fitzer-Attas K Frei MN Hassan, et al. 2010 Increased melanoma risk in Parkinson disease Arch Neurol 67 347 352 20212233 10.1001/archneurol.2010.1
3. V Bonifati P Rizzu MJ van Baren O Schaap GJ Breedveld E Krieger, et al. 2003 Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 256 259 12446870 10.1126/science.1077209 1:CAS:528:DC%2BD3sXhs1Gkuw%3D%3D (Pubitemid 36131051)
4. W Bruening BI Giasson AJ Klein-Szanto VM Lee JQ Trojanowski AK Godwin 2000 Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary Cancer 88 2154 2163 10813729 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9 1:CAS:528:DC%2BD3cXjtF2mu7o%3D (Pubitemid 30233219)
5. R Cesari ES Martin GA Calin F Pentimalli R Bichi H McAdams, et al. 2003 Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27 Proc Natl Acad Sci USA 100 5956 5961 12719539 10.1073/pnas.0931262100 1:CAS:528:DC%2BD3sXjvFOltrY%3D (Pubitemid 36581860)
6. R Constantinescu M Romer K Kieburtz 2007 Malignant melanoma in early Parkinson's disease: the DATATOP trial Mov Disord 22 720 722 17373726 10.1002/mds.21273 (Pubitemid 46800147)
7. KL Double GM Halliday PR Dunkley PW Dickson M Gerlach P Riederer 2010 Pigmentation in the human brain and risk of Parkinson's disease Ann Neurol 67 553 554 20437597 10.1002/ana.21882
8. JA Driver G Logroscino JE Buring JM Gaziano T Kurth 2007 A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease Cancer Epidemiol Biomarkers Prev 16 1260 1265 17548694 10.1158/1055-9965.EPI-07- 0038 (Pubitemid 46984968)
9. A Elbaz BJ Peterson P Yang JA Van Gerpen JH Bower DM Maraganore, et al. 2002 Nonfatal cancer preceding Parkinson's disease: a case-control study Epidemiology 13 157 164 11880756 10.1097/00001648-200203000-00010 (Pubitemid 34160490)
10. JM Elwood SM Whitehead J Davison M Stewart M Galt 1990 Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn Int J Epidemiol 19 801 810 2084006 10.1093/ije/19.4.801 1:STN:280:DyaK3M7ptlSjsw%3D%3D
11. J Ferreira JM Silva R Freire J Pignatelli LC Guedes A Feijó, et al. 2007 Skin cancers and precancerous lesions in Parkinson's disease patients Mov Disord 22 1471 1475 17516496 10.1002/mds.21575 (Pubitemid 47280634)
12. KH Fiala J Whetteckey BV Manyam 2003 Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 9 321 327 12853231 10.1016/S1353-8020(03)00040-3 (Pubitemid 36809033)
13. X Gao KC Simon J Han MA Schwarzschild A Ascherio 2009 Family history of melanoma and Parkinson disease risk Neurology 73 1286 1291 19841380 10.1212/WNL.0b013e3181bd13a1 1:STN:280:DC%2BD1Mjgt1yntw%3D%3D
14. X Gao KC Simon J Han MA Schwarzschild A Ascherio 2009 Genetic determinants of hair color and Parkinson's disease risk Ann Neurol 65 76 82 19194882 10.1002/ana.21535
15. H Gurney A Coates R Kefford 1991 The use of L-dopa and carbidopa in metastatic malignant melanoma J Invest Dermatol 96 85 87 1987300 10.1111/1523-1747.ep12515896 1:STN:280:DyaK3M7gtVyhtA%3D%3D
16. R Inzelberg J Jankovic 2007 Are Parkinson disease patients protected from some but not all cancers? Neurology 69 1542 1550 17699801 10.1212/01.wnl. 0000277638.63767.b8 (Pubitemid 47537862)
17. Israel National Cancer Registry (2006) Available at: http://www.health. gov.il/pages/default.asp?maincat22&catId196&PageId1583
18. B Jansson J Jankovic 1985 Low cancer rates among patients with Parkinson's disease Ann Neurol 17 505 509 4004173 10.1002/ana.410170514 1:STN:280:DyaL2M3itl2nug%3D%3D (Pubitemid 15019991)
19. RH Kim M Peters Y Jang W Shi M Pintilie GC Fletcher, et al. 2005 DJ-1, a novel regulator of the tumor suppressor PTEN Cancer Cell 7 263 273 15766664 10.1016/j.ccr.2005.02.010 1:CAS:528:DC%2BD2MXivFCqu7w%3D (Pubitemid 40568685)
20. AN Lieberman JL Shupack 1974 Levodopa and melanoma Neurology 24 340 343 4856355 1:STN:280:DyaE2c7islehsg%3D%3D
21. CB Lucking A Durr V Bonifati J Vaughan G De Michele T Gasser, et al. 2000 Association between early-onset Parkinson's disease and mutations in the parkin gene N Engl J Med 342 1560 1567 10824074 10.1056/NEJM200005253422103 1:CAS:528:DC%2BD3cXktVCgtbs%3D (Pubitemid 30340501)
22. Y Minami R Yamamoto M Nishikouri A Fukao S Hisamichi 2000 Mortality and cancer incidence in patients with Parkinson's disease J Neurol 247 429 434 10929271 10.1007/s004150070171 1:STN:280:DC%2BD3M%2FktVygtg%3D%3D (Pubitemid 30433556)
23. JH Olsen 1997 Avoidable cancers in the Nordic countries. Aims and background APMIS Suppl 76 1 8 9462817 1:STN:280:DyaK1c7it1Knuw%3D%3D
24. JH Olsen S Friis K Frederiksen 2006 Malignant melanoma and other types of cancer preceding Parkinson disease Epidemiology 17 582 587 16837822 10.1097/01.ede.0000229445.90471.5e (Pubitemid 44223068)
25. W Pfutzner B Przybilla 1997 Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature J Am Acad Dermatol 37 332 336 9270541 10.1016/S0190-9622(97)80385-4 1:STN:280:DyaK2svhs1Gqsw%3D%3D (Pubitemid 27350006)
26. MH Polymeropoulos C Lavedan E Leroy SE Ide A Dehejia A Dutra, et al. 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 2045 2047 9197268 10.1126/science.276.5321.2045 1:CAS:528:DyaK2sXkt1altr4%3D (Pubitemid 27443610)
27. FH Rampen 1985 Levodopa and melanoma: three cases and review of literature J Neurol Neurosurg Psychiatry 48 585 588 4009196 10.1136/jnnp.48.6. 585 1:STN:280:DyaL2M3js1ertg%3D%3D (Pubitemid 15025404)
28. DS Rigel Z Patel J Bolognia D Eichler DL Ellis RJ Friedman 2006 Evaluation of Parkinson's disease (PD) prevalence in patients with malignant melanoma (MM) Mov Disord 21 suppl 13 S58
29. SR Schwid J Bausch D Oakes L Schuchter C Tanner M Forrest, et al. 2010 Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease Mov Disord 25 1801 1808 20669311 10.1002/mds.23006
30. JF Siple DC Schneider WA Wanlass BK Rozenblatt 2000 Levodopa therapy and the risk of malignant melanoma Ann Pharmacother 34 382 385 10917387 10.1345/aph.19150 1:CAS:528:DC%2BD3cXitVCgsr4%3D (Pubitemid 30133603)
31. JL Skibba J Pinckley EF Gilbert RO Jonshon 1972 Multiple primary melanoma following administration of levodopa Arch Pathol 93 556 561 5025039 1:STN:280:DyaE387otFWluw%3D%3D
32. AJ Sober MM Wick 1978 Levodopa therapy and malignant melanoma JAMA 240 554 555 671667 10.1001/jama.240.6.554 1:STN:280:DyaE1c3itV2lsg%3D%3D (Pubitemid 9058780)
33. AB West VL Dawson TM Dawson 2005 To die or grow: Parkinson's disease and cancer Trends Neurosci 28 348 352 15913799 10.1016/j.tins.2005.05.002 1:CAS:528:DC%2BD2MXlsVequrc%3D (Pubitemid 40853857)
34. R Zanetti D Loria S Rosso 2006 Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature Melanoma Res 16 201 206 16718266 10.1097/01.cmr.0000215043.61306.d7 1:CAS:528: DC%2BD28Xksl2hsLw%3D (Pubitemid 44085093)